Study guide

8.3 Neonatal Arrhythmias, Cardiogenic Shock & Post-Resuscitation Care

Neonatal Pediatric Transport C-NPT

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The C-NPT Exam

About the C-NPT Exam: 2026 Format, Eligibility & Content Outline

2 Chapter 1: Transport Systems, Regulatory Framework & Legal Issues

1.1 Transport System Architecture, Accreditation (CAMTS) & Dispatch Triage 1.2 Regulatory & Legal Mandates: EMTALA, HIPAA, Consent & Documentation 1.3 Medical Direction, Scope of Practice & Ethical Considerations

3 Chapter 2: Safety, Communication, Crew Resource Management & Transport Environment

2.1 Crew Resource Management (CRM), Situational Awareness & Sterile Cockpit 2.2 Aircraft & Ground Ambulance Operations, Landing Zones & Vehicle Dynamics 2.3 Environmental Hazards, Weather Minimums & In-Flight Emergency Procedures 2.4 Communication in Transport: Peer Handoffs, Age-Appropriate Care, Families & Crew Stressors 2.5 Infection Control, PPE, Scene Safety & Disaster/Evacuation Planning

4 Chapter 3: Flight Physiology & Environmental Stressors

3.1 Physical Gas Laws & Transport Implications (Boyle, Dalton, Charles, Henry, Graham) 3.2 Altitude Hypoxia, Barometric Pressure Changes & Dysbarism 3.3 Acceleration Forces (G-forces), Vibration & Acoustic Stress in Transit 3.4 Thermoregulation Physics & Neutral Thermal Environment in Transit

5 Chapter 4: Invasive Procedures & Transport Monitoring

4.1 Advanced Airway Management & Endotracheal Intubation in Transit 4.2 Pleural Decompression (Needle Thoracostomy & Chest Tube Management) 4.3 Vascular Access: Umbilical Lines (UAC/UVC), Intraosseous (IO) & Arterial Lines

6 Chapter 5: Transport Equipment, Respiratory Physiology & Mechanical Ventilation

5.1 Transport Incubators (Isolettes), Thermal Control & Electrical/Gas Power Systems 5.2 Portable Ventilators & Modes (PC, VC, PRVC, High Frequency) 5.3 Gas Cylinder Duration Calculations, Oxygen Delivery & Inhaled Nitric Oxide (iNO) 5.4 Respiratory Physiology: Acid-Base Balance, Oxygenation, Lung Mechanics & Troubleshooting

7 Chapter 6: Transport Pharmacology, Resuscitation, Fluids & Electrolytes

6.1 Vasoactive Infusions & Inotropes (Epinephrine, Dopamine, Dobutamine, Milrinone) 6.2 Sedation, Analgesia & Neuromuscular Blockade in Transport 6.3 Prostaglandin E1 (Alprostadil) & Surfactant Replacement Therapy 6.4 Resuscitation Protocols (NRP, PALS) & Shock Fluid Resuscitation 6.5 Antimicrobial Pharmacology in Neonatal & Pediatric Transport 6.6 Post-Resuscitation Care, Defibrillation & Cardioversion in Transit, ECMO Indications & the Transport-vs-Stay Decision 6.7 Fluid & Electrolyte Therapy Across the Ages: Maintenance, Dehydration, Fluid Overload & Electrolyte Emergencies

8 Chapter 7: Neonatal Respiratory Pathologies & Management

7.1 Respiratory Distress Syndrome (RDS) & Surfactant Deficiency 7.2 Meconium Aspiration Syndrome (MAS) & Persistent Pulmonary Hypertension (PPHN) 7.3 Transient Tachypnea (TTN), Neonatal Pneumothorax & Congenital Diaphragmatic Hernia (CDH) 7.4 Neonatal Upper Airway Anomalies, Aspiration, Pneumonia, Chronic Lung Disease & Respiratory Failure

9 Chapter 8: Neonatal Cardiovascular Critical Care

8.1 Ductal-Dependent Cyanotic Congenital Heart Defects (TGA, TOF, Tricuspid Atresia) 8.2 Ductal-Dependent Systemic Blood Flow Lesions (HLHS, Coarctation, Interrupted Arch) 8.3 Neonatal Arrhythmias, Cardiogenic Shock & Post-Resuscitation Care 8.4 Acyanotic Congenital Heart Lesions, Patent Ductus Arteriosus, Obstructed TAPVR & Neonatal Heart Failure

10 Chapter 9: Neonatal Neurological & Metabolic Crises

9.1 Hypoxic-Ischemic Encephalopathy (HIE) & Passive/Active Therapeutic Hypothermia 9.2 Neonatal Seizures & Intraventricular Hemorrhage (IVH) 9.3 Neonatal Hypoglycemia, Electrolyte Derangements & Hyperbilirubinemia 9.4 Subgaleal Hemorrhage, Neonatal Sepsis & Meningitis, and Perinatal Substance Exposure (NOWS)

11 Chapter 10: Neonatal Surgical Emergencies, Neural Tube Defects & ELBW Care

10.1 Abdominal Wall Defects (Gastroschisis vs. Omphalocele) & TEF/Esophageal Atresia 10.2 Necrotizing Enterocolitis (NEC), Malrotation with Volvulus & Intestinal Obstruction 10.3 Care of the Extremely Low Birth Weight (ELBW) Infant (<1000g) in Transit 10.4 Neural Tube Defects: Myelomeningocele, Encephalocele & Transport of the Newborn With an Open Spinal Defect

12 Chapter 11: Pediatric Respiratory Emergencies

11.1 Acute Upper Airway Obstruction (Croup, Epiglottitis, Bacterial Tracheitis, Foreign Body) 11.2 Lower Airway Crises: Status Asthmaticus & Severe Bronchiolitis 11.3 Pediatric Acute Respiratory Distress Syndrome (PARDS) & Severe Pneumonia

13 Chapter 12: Pediatric Shock & Cardiovascular Crises

12.1 Pathophysiology & Transport Management of Pediatric Septic Shock 12.2 Hypovolemic, Cardiogenic & Anaphylactic Shock in Children 12.3 Pediatric Cardiac Emergencies: SVT, Ventricular Arrhythmias & Myocarditis 12.4 Pediatric Cardiovascular Crises: Palliated Congenital Heart Disease, Pulmonary Hypertensive Crisis, Pericarditis & Tamponade, Hypertensive Emergency & Anterior Mediastinal Mass

14 Chapter 13: Pediatric Neurological Emergencies & Trauma

13.1 Status Epilepticus, Altered Mental Status & Meningitis/Encephalitis 13.2 Pediatric Traumatic Brain Injury (TBI) & Increased Intracranial Pressure (ICP) 13.3 Blunt/Penetrating Trauma, Spinal Motion Restriction & Thermal Burns 13.4 Non-Accidental Trauma, Smoke Inhalation (Carbon Monoxide & Cyanide) & Heat Illness

15 Chapter 14: Pediatric Toxicological, Environmental & Endocrine Emergencies

14.1 Common Pediatric Toxic Ingestions, Poisonings & Antidotes 14.2 Diabetic Ketoacidosis (DKA) & Environmental Emergencies (Submersion, Hypothermia) 14.3 Button Battery & Foreign-Body Ingestions, Bites & Envenomations, and Hazardous-Material Exposures

16 Chapter 15: Pediatric Metabolic & Hematologic Emergencies

15.1 Anemia, Sickle Cell Disease, Coagulopathies & Blood Product Administration 15.2 Oncologic Emergencies, Acute Kidney Injury & Pediatric Electrolyte Crises

8.3 Neonatal Arrhythmias, Cardiogenic Shock & Post-Resuscitation Care

Key Takeaways Explain This Topic AI

Neonatal Supraventricular Tachycardia (SVT) is characterized by a rapid, regular, narrow QRS complex rhythm (typically 220–300 bpm) with sudden onset and termination, absent P waves or retrograde P waves, and complete loss of physiological beat-to-beat heart rate variability.

Initial acute management of stable neonatal SVT employs the dive reflex via application of an ice-water bag to the upper face for 10–15 seconds (avoiding ocular pressure); if ineffective, rapid IV push Adenosine (0.1 mg/kg followed by rapid saline flush via proximal access) is first-line pharmacotherapy.

Unstable SVT presenting with shock, hypotension, or cardiac failure mandates immediate synchronized electrical cardioversion at 0.5–1.0 J/kg, escalating to 2.0 J/kg for refractory tachydysrhythmias.

Neonatal bradycardia (<100 bpm) is overwhelmingly secondary to hypoxemia, respiratory failure, or severe acidosis rather than primary nodal disease; immediate effective positive pressure ventilation and oxygenation take priority over pharmacological chronotropes.

Neonatal cardiogenic shock is distinguished from septic shock by pronounced hepatomegaly, gallop rhythm (S3/S4), and pulmonary venous congestion; management relies on inodilators like Milrinone (0.25–0.75 mcg/kg/min without bolus) or low-dose Epinephrine, while strictly avoiding aggressive fluid boluses that exacerbate heart failure.

Last updated: September 2026

Neonatal Arrhythmias, Cardiogenic Shock & Post-Resuscitation Care

Neonatal rhythm disturbances and low cardiac output states present complex diagnostic and therapeutic challenges during interfacility transport. The neonatal myocardium is structurally immature, with disorganized myofibrils, deficient sarcoplasmic reticulum, and blunted autonomic sympathetic innervation. Because the neonatal heart cannot significantly increase stroke volume, cardiac output is strictly heart-rate dependent, leaving infants vulnerable to tachyarrhythmias, bradycardias, and acute afterload elevation.

  • Neonatal Arrhythmias: Recognition & Electrophysiology
  • Supraventricular Tachycardia (SVT) vs. Sinus Tachycardia

Supraventricular Tachycardia is the most common pathological tachydysrhythmia in neonates, typically mediated by an accessory atrioventricular reentrant pathway (such as Wolff-Parkinson-White syndrome) or AV nodal reentry. Differentiating SVT from sinus tachycardia is vital:

Supraventricular Tachycardia (SVT): Rapid, unvarying, narrow-complex ventricular rate, typically 220 to 300 bpm . Features abrupt onset and termination ("on-off switch" kinetics). P waves are absent, obscured in the preceding T wave, or inverted (retrograde conduction). Decisively, SVT exhibits complete loss of physiological beat-to-beat variability during handling or rest.

Sinus Tachycardia: Ventricular rate usually <200–220 bpm with smooth beat-to-beat variability fluctuating with fever, pain, agitation, or volume status. Normal upright P waves precede each narrow QRS complex.

Acute Management of Neonatal SVT

Vagal Maneuver (The Diving Reflex): In hemodynamically stable neonates, stimulate the trigeminal-vagal arc to slow AV nodal conduction. Apply a sealed glove or bag containing crushed ice and cold water to the forehead, nose, and upper face for 10 to 15 seconds . Never apply ocular pressure—manual compression of the globes is strictly contraindicated due to the severe risks of retinal detachment and globe rupture. Never occlude the mouth or airway.

Adenosine Pharmacotherapy: If vagal maneuvers fail, Adenosine is the first-line medication. Adenosine binds myocardial A1 purinergic receptors, transiently blocking AV nodal conduction:

Dosing: Initial dose 0.1 mg/kg rapid IV push (maximum 6 mg). If ineffective within 1–2 minutes, administer 0.2 mg/kg (maximum 12 mg).

Technique: Adenosine has an ultra-short half-life (<10 seconds). Administer via a two-syringe stopcock at the most proximal venous or intraosseous site, followed immediately by an instantaneous 3 to 5 mL normal saline flush . Run a continuous rhythm strip during injection to record transient AV block or asystole.

Contraindicated Agent: Intravenous Verapamil is strictly contraindicated in infants under 1 year of age; it causes refractory electromechanical dissociation, profound hypotension, and cardiovascular collapse.

Synchronized Electrical Cardioversion: If the neonate is hemodynamically unstable (hypotension, poor perfusion, lethargy, pulmonary edema, or cardiogenic shock), perform immediate synchronized cardioversion at 0.5 to 1.0 J/kg . If refractory, escalate to 2.0 J/kg . Ensure SYNC mode is engaged to deliver the shock on the R wave, preventing the lethal "R-on-T" phenomenon that triggers ventricular fibrillation.

Neonatal Bradycardia & Congenital Complete Heart Block

Secondary Bradycardia: Neonatal bradycardia (heart rate <100 bpm, or <60 bpm requiring chest compressions) is almost universally secondary to hypoxemia, alveolar hypoventilation, or severe acidosis . The immediate, definitive treatment is establishing airway patency and delivering effective positive pressure ventilation (PPV) with supplemental oxygen . Atropine and chronotropes are ineffective if hypoxia and acidosis remain uncorrected.

Congenital Complete Heart Block (CCHB): A critical exception caused by transplacental transfer of maternal autoantibodies ( anti-Ro/SSA and anti-La/SSB ) from mothers with systemic lupus erythematosus or Sjögren's syndrome. Autoantibodies induce inflammation and irreversible calcification of the fetal AV node and bundle of His.

Features: Fixed, profound resting bradycardia (typically 40 to 70 bpm ) with complete AV dissociation, usually with a narrow-QRS junctional escape rhythm.

Management: Unresponsive to atropine due to anatomical nodal disruption. Chronotropic infusions like Isoproterenol (0.05–0.5 mcg/kg/min) or Epinephrine (0.05–0.3 mcg/kg/min) stimulate the escape pacemaker. For low cardiac output or hypotension, emergent transcutaneous or temporary pacing is indicated.

Neonatal Cardiogenic Shock vs. Septic Shock

Differentiating cardiogenic from septic shock is critical to avoid lethal fluid overload:

Clinical Parameter Neonatal Cardiogenic Shock Neonatal Septic Shock (Cold Phenotype)

Primary Pathophysiology Pump failure, elevated ventricular filling pressures Cytokine-mediated vasoplegia, capillary leak

Hepatic Examination Marked hepatomegaly (>3–4 cm below costal margin, firm) Normal liver span or minimally palpable (<1–2 cm)

Pulmonary Findings Tachypnea, rales/crackles, pulmonary venous congestion Clear breath sounds initially unless pneumonia coexists

Auscultation Ventricular gallop (S3 or S4), possible cardiac murmur Tachycardia, no gallop, clear heart tones

Chest Radiograph Cardiomegaly (cardiothoracic ratio >0.60), pulmonary edema Normal heart size, clear or patchy infiltrate

Response to Fluid Bolus Deterioration: worsening pulmonary edema, frothy secretions Transient or sustained improvement in perfusion

Targeted Inotropic Support for the Failing Myocardium

Because the neonatal ventricle operates near the peak of its Frank-Starling curve, fluid boluses in cardiogenic shock exacerbate ventricular dilation and alveolar flooding. Fluid boluses must be strictly restricted (5 mL/kg aliquots only if true hypovolemia is documented). Inotropic therapies include:

Milrinone (0.25 to 0.75 mcg/kg/min): PDE-3 inhibitor that enhances contractility, accelerates diastolic relaxation (lusitropy), and decreases SVR and PVR (inodilator) without increasing myocardial oxygen consumption. In transport, omit the loading bolus to avoid sudden vasodilation and hypotension.

Dobutamine (2 to 20 mcg/kg/min): Beta-1 inotrope with mild beta-2 vasodilation, augmenting cardiac output while reducing filling pressures.

Low-Dose Epinephrine (0.03 to 0.1 mcg/kg/min): Provides direct beta-1 receptor stimulation, bypassing depleted neonatal norepinephrine stores. Avoid pure alpha-agonists that elevate afterload against a failing ventricle.

Post-Resuscitation Critical Care in Transport

Targeted Temperature Management: Strict avoidance of hyperthermia ( T > 38.0 ∘ C T > 38.0^\circ\text{C} T > 38. 0 ∘ C ) is mandatory; fever accelerates cerebral metabolic oxygen consumption ( C M R O 2 CMRO_2 CMR O 2 ​ ) and worsens post-ischemic neuronal death. Maintain core normothermia ( 36.5 ∘ C 36.5^\circ\text{C} 36. 5 ∘ C to 37.5 ∘ C 37.5^\circ\text{C} 37. 5 ∘ C ), or initiate active therapeutic hypothermia ( 33.5 ∘ C 33.5^\circ\text{C} 33. 5 ∘ C ) if the infant meets criteria for moderate-to-severe hypoxic-ischemic encephalopathy (HIE).

Metabolic & Glycemic Homeostasis: Maintain blood glucose strictly between 70 and 120 mg/dL with continuous dextrose infusions (GIR 4–8 mg/kg/min). Hypoglycemia (<45–50 mg/dL) causes neuronal apoptosis, while hyperglycemia (>150–180 mg/dL) exacerbates cerebral lactic acidosis.

Invasive Hemodynamic Monitoring: Secure an umbilical arterial catheter (UAC) or peripheral arterial line for continuous mean arterial pressure (MAP) monitoring, targeting a MAP ≥ \ge ≥ gestational age in weeks (or ≥ 40 – 45 mmHg \ge 40–45\text{ mmHg} ≥ 40–45 mmHg in term infants). Track serial lactate clearance and monitor hourly urine output, targeting >1–2 mL/kg/hr as the benchmark of visceral perfusion.

Comparison of Neonatal Arrhythmias & Shock States

Condition Core ECG / Hemodynamic Features Primary Etiology First-Line Transport Resuscitation Strictly Contraindicated Actions

SVT Rate 220–300 bpm, narrow QRS, no variability Re-entrant accessory pathway (e.g., WPW) Ice to face (10–15 s); Adenosine (0.1 mg/kg rapid push); Cardioversion (0.5–1 J/kg) Never use IV Verapamil; never apply ocular pressure

CCHB Rate 40–70 bpm, AV dissociation, usually narrow-QRS junctional escape Maternal anti-SSA/Ro, anti-SSB/La antibodies Isoproterenol (0.05–0.5 mcg/kg/min); Epinephrine; Emergency pacing Atropine is ineffective; do not delay pacing if hypotensive

Cardiogenic Shock Poor perfusion, hepatomegaly, gallop, crackles Myocardial ischemia, structural CHD, myocarditis Fluid restriction; Milrinone (0.25–0.75 mcg/kg/min, NO bolus); low-dose Epi Aggressive crystalloid boluses (triggers lethal pulmonary edema)

Septic Shock Mottled or flushed, clear lungs, normal liver Bacterial or viral systemic sepsis Cautious crystalloid boluses (10–20 mL/kg); Epinephrine infusion (0.05–0.3 mcg/kg/min) Delayed vasoactive support; unmonitored fluid overloading

Realistic Transport Scenario: Unstable Neonatal SVT Conversion En Route

A neonatal transport crew is transferring a 10-day-old infant (weight 3.5 kg) to a pediatric cardiac ICU. En route, the cardiac monitor alarms for a sudden change from sinus rhythm (145 bpm) to an unvarying narrow-complex tachycardia at 290 bpm. Over 3 minutes, the infant becomes pale and lethargic, capillary refill extends to 4.5 seconds, and blood pressure drops to 48/26 mmHg (mean 33 mmHg). The transport physician immediately identifies unstable SVT. The team attaches pediatric defibrillator pads, verifies 'SYNC' mode, and charges to 3 Joules (~0.85 J/kg). A single synchronized shock is delivered, producing brief sinus pauses followed by normal sinus rhythm at 150 bpm. Blood pressure rapidly improves to 72/44 mmHg (mean 53 mmHg) and capillary refill shortens to 2 seconds, stabilizing the infant for transit.

Clinical Pearls for Arrhythmias & Cardiogenic Shock

Important

Neonatal Bradycardia is Hypoxia Until Proven Otherwise: Never administer atropine for neonatal bradycardia without first establishing airway patency, ventilation, and oxygenation. Bradycardia is the terminal response to tissue hypoxia.

Tip

Stopcock Technique for Adenosine: Adenosine's half-life is under 10 seconds. Administer through a three-way stopcock at the most proximal IV/IO port, immediately flushed with a rapid 3–5 mL normal saline bolus.

Note

Fluid Restriction in Cardiogenic Shock: When examining an infant in shock, palpate the liver. If the liver edge is 4 cm below the costal margin and lung crackles are present, stop fluid infusions. Fluid boluses overdistend non-compliant neonatal ventricles and precipitate lethal pulmonary edema.

Loading diagram... Neonatal Tachyarrhythmia & SVT Clinical Management Algorithm